Overcoming resistance to second-generation antiandrogens in prostate cancer

Robert Dreicer, MD, discusses emerging strategies for overcoming resistance to second-generation antiandrogens in prostate cancer. Second-generation antiandrogens approved by the FDA for the treatment of patients with prostate cancer include abiraterone acetate (Zytiga), enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa).

Dreicer is associate director for Clinical Research and deputy director of the University of Virginia Cancer Center; section head of Medical Oncology and co-director of the Paul Mellon Urologic Institute; and professor of Medicine and Urology at the University of Virginia School of Medicine.